Ireland
--:--IST
Latest
Clinical Trials in France / NCT04702932
Starting soon Observational

Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies

NCT04702932 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2021-09-01
Last updated
2021-01-11

Condition(s) studied

Monoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaWaldenstrom Macroglobulinemia

Study summary

Patients with monoclonal gammopathies either benign or malignant may develop inflammatory symptoms such as Schnitzler syndrome. We proposed to name those cases as monoclonal gammopathy of inflammatory significance, or MGIS.

The aim of the study is to search for inflammatory pathway that may be activated in case MGIS and to search if the genetic of tumoral cell could explain those activations.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient over 18 years of age with the capacity to give express free and informed consent. * Patient followed in one of the services participating in the study and meeting the 2 following conditions 1. have myelodysplastic syndrome, or multiple myeloma, or monoclonal gammopathy of undetermined significance, or Schnitzler's syndrome. 2. have a fever of undetermined etiology associated with one of the following symptoms: rash, arthralgia or arthritis, serositis, abdominal pain. Exclusion Criteria: * Patient incapable of giving express free and informed consent. * Subject under guardianship, curatorship or safeguarding of justice. * Subject does not speak French. * Subject incapable of answering questions or expressing himself/herself. * Presence of a differential diagnosis that may explain the patient's symptoms.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Service de Médecine Interne Paris France

More Assistance Publique - Hôpitaux de Paris trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04702932 on ClinicalTrials.gov ↗ ← All trials in France